Eupraxia Pharmaceuticals Files 6-K Report
Ticker: EPRX · Form: 6-K · Filed: Sep 11, 2024 · CIK: 1581178
Sentiment: neutral
Topics: reporting, foreign-private-issuer, press-release
TL;DR
Eupraxia Pharma dropped a 6-K with a press release on Sept 11 - check it for news.
AI Summary
Eupraxia Pharmaceuticals Inc. filed a Form 6-K on September 11, 2024, reporting information for the month of September 2024. The filing includes Exhibit 99.1, a press release dated September 11, 2024. The company is incorporated in Canada and its principal executive office is located in Victoria, British Columbia.
Why It Matters
This filing provides an update on Eupraxia Pharmaceuticals' reporting status and includes a press release, which may contain material information for investors.
Risk Assessment
Risk Level: low — This filing is a routine report of foreign private issuer information and does not contain significant financial or operational disclosures that would indicate high risk.
Key Players & Entities
- Eupraxia Pharmaceuticals Inc. (company) — Registrant
- September 11, 2024 (date) — Filing date and press release date
- Victoria, British Columbia, Canada (location) — Registrant's principal executive office
- Bruce C (person) — Signatory for Eupraxia Pharmaceuticals Inc.
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers that are required to furnish information to the SEC that they have made or are required to make public pursuant to the laws of their home country.
What specific document is included as part of this 6-K filing?
Exhibit 99.1, a Press Release dated September 11, 2024, is included as part of this report.
When was this Form 6-K filed with the SEC?
This Form 6-K was filed on September 11, 2024.
Where is Eupraxia Pharmaceuticals Inc. located?
Eupraxia Pharmaceuticals Inc.'s principal executive office is located at 201-2067 Cadboro Bay Road, Victoria, British Columbia, Canada.
Does Eupraxia Pharmaceuticals file annual reports under Form 20-F or Form 40-F?
Eupraxia Pharmaceuticals Inc. files annual reports under Form 40-F.
Filing Stats: 169 words · 1 min read · ~1 pages · Grade level 14.6 · Accepted 2024-09-11 07:02:25
Filing Documents
- form6k.htm (6-K) — 11KB
- ex991.htm (EX-99.1) — 28KB
- logo.jpg (GRAPHIC) — 23KB
- 0001279569-24-001099.txt ( ) — 72KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Eupraxia Pharmaceuticals Inc. Date: September 11, 2024 By: /s/ Bruce Cousins Name: Bruce Cousins Title: President and Chief Financial Officer